Novozymes Financial Statements From 2010 to 2024
| NVZMF Stock | USD 57.50 0.35 0.61% |
Check Novozymes A/S financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Novozymes A/S's main balance sheet or income statement drivers, such as , as well as many indicators such as . Novozymes financial statements analysis is a perfect complement when working with Novozymes A/S Valuation or Volatility modules.
Novozymes |
Novozymes AS B Company Return On Equity Analysis
Novozymes A/S's Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.
Current Novozymes A/S Return On Equity | 0.28 |
Most of Novozymes A/S's fundamental indicators, such as Return On Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Novozymes AS B is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
| Competition |
Based on the latest financial disclosure, Novozymes AS B has a Return On Equity of 0.2789. This is 69.35% lower than that of the Basic Materials sector and 95.26% lower than that of the Specialty Chemicals industry. The return on equity for all United States stocks is 189.97% lower than that of the firm.
Novozymes AS B Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novozymes A/S's current stock value. Our valuation model uses many indicators to compare Novozymes A/S value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novozymes A/S competition to find correlations between indicators driving Novozymes A/S's intrinsic value. More Info.Novozymes AS B is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers reporting about 0.38 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Novozymes AS B is roughly 2.63 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novozymes A/S's earnings, one of the primary drivers of an investment's value.About Novozymes A/S Financial Statements
Novozymes A/S stakeholders use historical fundamental indicators, such as Novozymes A/S's revenue or net income, to determine how well the company is positioned to perform in the future. Although Novozymes A/S investors may analyze each financial statement separately, they are all interrelated. For example, changes in Novozymes A/S's assets and liabilities are reflected in the revenues and expenses on Novozymes A/S's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Novozymes AS B. Please read more on our technical analysis and fundamental analysis pages.
Novozymes AS produces and sells industrial enzymes, microorganisms, and probiotics in Europe, the Middle East, Africa, North America, the Asia Pacific, and Latin America. The company was founded in 1925 and is headquartered in Bagsvaerd, Denmark. NOVOZYMES is traded on OTC Exchange in the United States.
Currently Active Assets on Macroaxis
Other Information on Investing in Novozymes Pink Sheet
Novozymes A/S financial ratios help investors to determine whether Novozymes Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Novozymes with respect to the benefits of owning Novozymes A/S security.